Article thumbnail

Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition

By Simona Corso, Elena Ghiso, Virna Cepero, J Rafael Sierra, Cristina Migliore, Andrea Bertotti, Livio Trusolino, Paolo M Comoglio and Silvia Giordano
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). A: Oncogene addiction. Cancer Res
  2. (2008). A: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
  3. (2008). Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev
  4. (2005). Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol
  5. (2007). BS: Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res
  6. (2005). Cancer therapy: can the challenge be MET? Trends Mol Med
  7. (2008). Comb MJ: Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA
  8. (1991). Comoglio P: Cterminal truncated forms of Met, the hepatocyte growth factor receptor. Mol Cell Biol
  9. (1994). Comoglio PM: A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell
  10. (1991). Comoglio PM: c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene
  11. (1998). Comoglio PM: Overexpression of the RON gene in human breast carcinoma. Oncogene
  12. (1988). Comoglio PM: p145, a protein with associated tyrosine kinase activity in a human gastric carcinoma cell line. Mol Cell Biol
  13. (2000). Comoglio PM: Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene
  14. (2004). Comoglio PM: Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell
  15. (2002). Comoglio PM: The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol
  16. (1989). Comoglio PM: Tyrosine kinase receptor indistinguishable from the c-met protein. Nature
  17. DA: Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-
  18. (2003). DB: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res
  19. (2007). DF: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
  20. (2001). EGFR and cancer prognosis.
  21. (2005). Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.
  22. (2009). ErbB receptors and signaling pathways in cancer.
  23. (2006). Figueiredo C: Helicobacter pylori induces gastric epithelial cell invasion in a c-Met and type IV secretion system-dependent manner.
  24. (2009). Gastric cancer in the era of molecularly targeted agents: current drug development strategies.
  25. (2000). Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet
  26. (2000). Heldin NE: Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res
  27. (2007). Janne PA: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science
  28. (2007). MI: ErbB receptors: from oncogenes to targeted cancer therapies.
  29. (2008). Molecular cancer therapy: Can our expectation be MET?
  30. (2000). Naldini L: Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy.
  31. (2007). RI: Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res
  32. (2005). Roberts TG Jr: Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer
  33. (2005). S: TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene
  34. (1992). Saglio G: Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. Cancer Genet Cytogenet
  35. (2008). Salgia R: Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer.
  36. (2007). Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene
  37. (2008). Solit DB, Weiser MR: HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogeneaddicted gastric cancer cells. Mol Cancer Ther
  38. (2006). Song E: Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo.
  39. (2008). Suriano G: Epidermal growth factor receptor structural alterations in gastric cancer.
  40. (1999). The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer
  41. (2008). Trusolino L: Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov
  42. (2002). Trusolino L: Invasive growth: from development to metastasis.
  43. (2000). Weinberg RA: The hallmarks of cancer. Cell
  44. (2003). Woude GF Vande: Met, metastasis, motility and more. Nat Rev Mol Cell Biol
  45. (2007). Yarden Y: Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene